Bharat Parenterals Ltd said its subsidiary, Innoxel Lifesciences, has received five observations from the United States Food and Drug Administration (USFDA) following a recent USFDA inspection at its Vadodara facility.
The inspection was carried out between April 13 and April 17, 2026, at the company’s General Injectables Block, and concluded on April 20. At the end of the review, the USFDA issued five observations under the Voluntary Action Indicated (VAI) category. This classification typically means that while certain issues were identified, they are not serious enough to trigger immediate regulatory action.
The company stated that it will respond to the observations within the prescribed timeline and is awaiting the final EIR report from the US regulator. Such inspections are a routine part of ensuring that pharmaceutical manufacturing companies meet global quality and safety standards, especially when supplying to regulated markets.
Also Read: India Leads Global Shift Toward AI-Driven Personal Health Care
The Vadodara facility plays a key role in Innoxel’s operations, particularly in manufacturing sterile injectables. These medicines are exported to markets like the United States and Europe, supporting the company’s growing pharma exports business and reinforcing its presence in drug manufacturing India.
In its response, the company indicated that the observations were largely procedural and do not point to major gaps in regulatory compliance. It also emphasized its ongoing commitment to strengthening manufacturing practices and maintaining high-quality standards across operations.
Bharat Parenterals manufactures a wide range of pharmaceutical products, including injectables, oral formulations, and anti-retroviral drugs. The company has been working to expand its footprint in both domestic and international markets.
On the financial side, the company reported a consolidated net loss of ?4.39 crore in the third quarter of FY26, compared to ?1.67 crore in the same period last year. Revenue also saw a decline of nearly 10% year-on-year.
Despite the USFDA observations, the company’s stock showed a slight uptick, reflecting steady investor confidence in its long-term prospects and compliance track record.
.jpg)
.jpg)
